Product pipeline

Genmab has two partnered products on the market, DARZALEX® (daratumumab) and Arzerra® (ofatumumab), and is developing a clinical pipeline of antibody therapeutics for the treatment of cancer. 

Products in development

Products in development

Our antibodies are being evaluated in numerous clinical studies

Lab photo

Daratumumab

Our second approved product, first-in-class CD38 antibody for multiple myeloma, in development with Janssen Biotech, Inc. 

Lab photo

Tisotumab vedotin

Our first antibody-drug conjugate in development for solid tumors in a 50:50 partnership with Seattle Genetics

Lab photo

Pre-clinical

Our pre-clinical product candidates help to fuel our future clinical pipeline